Novo Nordisk AS (NVO)
105.06
+2.43
(+2.37%)
USD |
NYSE |
Nov 22, 16:00
105.08
+0.02
(+0.02%)
Pre-Market: 20:00
Novo Nordisk Free Cash Flow: 9.828B for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | 9.828B |
| June 30, 2024 | 9.505B |
| March 31, 2024 | 7.330B |
| December 31, 2023 | 10.16B |
| September 30, 2023 | 11.76B |
| June 30, 2023 | 9.713B |
| March 31, 2023 | 9.409B |
| December 31, 2022 | 9.092B |
| September 30, 2022 | 7.739B |
| June 30, 2022 | 8.391B |
| March 31, 2022 | 9.284B |
| December 31, 2021 | 7.577B |
| September 30, 2021 | 6.278B |
| June 30, 2021 | 5.340B |
| March 31, 2021 | 4.935B |
| December 31, 2020 | 4.577B |
| September 30, 2020 | 7.055B |
| June 30, 2020 | 7.060B |
| March 31, 2020 | 5.511B |
| December 31, 2019 | 5.331B |
| September 30, 2019 | 5.583B |
| June 30, 2019 | 4.762B |
| March 31, 2019 | 5.013B |
| December 31, 2018 | 5.102B |
| September 30, 2018 | 4.741B |
| Date | Value |
|---|---|
| June 30, 2018 | 5.386B |
| March 31, 2018 | 4.593B |
| December 31, 2017 | 4.950B |
| September 30, 2017 | 5.902B |
| June 30, 2017 | 5.837B |
| March 31, 2017 | 6.504B |
| December 31, 2016 | 5.952B |
| September 30, 2016 | 5.776B |
| June 30, 2016 | 5.544B |
| March 31, 2016 | 5.178B |
| December 31, 2015 | 4.743B |
| September 30, 2015 | 4.753B |
| June 30, 2015 | 5.048B |
| March 31, 2015 | 4.785B |
| December 31, 2014 | 4.884B |
| September 30, 2014 | 4.655B |
| June 30, 2014 | 3.700B |
| March 31, 2014 | 3.478B |
| December 31, 2013 | 3.971B |
| September 30, 2013 | 3.312B |
| June 30, 2013 | 3.461B |
| March 31, 2013 | 3.417B |
| December 31, 2012 | 3.211B |
| September 30, 2012 | 3.517B |
| June 30, 2012 | 3.720B |
Free Cash Flow Range, Past 5 Years
4.577B
Minimum
Dec 2020
11.76B
Maximum
Sep 2023
7.794B
Average
7.658B
Median
Free Cash Flow Benchmarks
| Ascendis Pharma AS | -- |
| Amgen Inc | 6.283B |
| AstraZeneca PLC | 6.757B |
| Viking Therapeutics Inc | -74.25M |
| Evaxion Biotech AS | -- |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 6.658B |
| Cash from Investing (Quarterly) | -3.131B |
| Cash from Financing (Quarterly) | -2.741B |
| Free Cash Flow Per Share (Quarterly) | 1.064 |
| Free Cash Flow to Equity (Quarterly) | 4.406B |
| Free Cash Flow to Firm (Quarterly) | 4.748B |
| Free Cash Flow Yield | 2.09% |